Whiting succeeds Jill Schiaparelli, who served in the corner office since 2018. He takes over at the Columbus, Ohio-based non-invasive neuromodulation technology developer advancing a therapy for overactive bladder (OAB).
Avation develops Vivally, a non-invasive, FDA-cleared wearable neuromodulation system. It delivers closed-loop, autonomously adjusted electrical stimulation to treat patients with urge urinary incontinence (UUI) and urinary urgency caused by OAB syndrome. The system uses proprietary algorithms and electromyographic sensors to detect and calibrate the level of energy delivered to the tibial nerve during stimulation. This ensures optimal, customized therapeutic output in a real-time, closed-loop operation.
Worn on the ankle, Vivally only requires 30-minute therapy sessions as infrequently as once per week. It requires no surgery and no drugs, unlike other implantable neuromodulation approaches for bladder treatment.
“I am excited to join the Avation Medical team as we accelerate the commercialization of this groundbreaking technology to reach patients across the U.S. by working closely with physicians and payors,” said Whiting. “The Vivally system is the first non-invasive, physiologic closed-loop neuromodulation treatment offering at-home therapy for the more than 9 million people receiving care for symptoms of overactive bladder (OAB).”
Whiting brings more than 25 years of experience in the medtech industry. Before joining Avation, he served as president of Zoll Cardiac Management Solutions for more than eight years. Before that, he held the position of VP of marketing and clinical operations there, beginning in 2008.
“As Avation commercially scales, Jason will bring valuable experience and leadership that we expect will accelerate growth and profitability,” said Tom Shehab, MD, Chairman of the Avation Medical board of directors. “Jason has successfully brought wearable technologies to market and created new categories in the MedTech space. On behalf of the entire Board, I would like to thank Jill for her service to the organization and her role in guiding the Company to this stage.”
